SueWallSt

$WPP told investors 2025 would be steady even “cautiously optimistic.” Then came the surprise: plummeting revenues, CEO retirement, and a trading update that sparked an 18% stock drop. In this episode of Sue Wall Street, we break down the securities class action accusing the global ad giant of misleading investors with overconfident projections. If you're into ad tech, investor risk, or corporate spin, this one's for you.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

When $SVRA Savara Inc. filed its long-awaited FDA application, investors cheered—until the FDA refused to even review it. In this episode, we dive into the unfolding securities class action accusing Savara of misleading shareholders about its incomplete drug submission. Biotech investors, pharma followers, and Wall Street skeptics this one's for you. Expect sharp breakdowns, timely analysis, and a dose of biotech drama.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

A fresh class action lawsuit is shaking up $TROX Tronox Holdings, after investors claim the company misled them with glowing projections and shaky forecasting. In this episode of Sue Wall Street, we dive into how a drop in demand, a slashed dividend, and a brutal 38% stock plunge triggered legal action. If you're an investor, trader, or just love corporate drama, tune in for sharp insights, expert analysis, and sarcastic pigment puns.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

Was $VFC walking investors into a turnaround—or a trap? In this episode of Sue Wall Street, we dive into the class action lawsuit against V.F. Corporation, the company behind Vans, The North Face, and Timberland. While hyping its “Reinvent” strategy, VFC allegedly hid plans for a second major reset—until surprise earnings revealed a 20% Vans revenue drop. If you follow retail stocks, brand comebacks, or securities litigation, this one's for you.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

Did $CYTK gamble with the FDA and lose investor trust? In this episode of Sue Wall Street, we unpack the class action lawsuit against Cytokinetics Inc. Despite strong Phase 3 results, the company skipped a critical REMS in their NDA, delaying drug approval and tanking their stock. If you're into biotech moves, FDA filings, or securities law drama, this deep dive is for you. Learn how one missing document may cost shareholders millions.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Was $FLR engineering confidence or just misleading investors? In this episode of Sue Wall Street, we dive into the securities class action lawsuit against Fluor Corporation. If you're tracking construction giants, infrastructure deals, or suspiciously sunny earnings calls, this one’s for you. We unpack how project delays, cost overruns, and executive stock sales all led to a brutal 27% drop in one day—and a whole lot of legal fallout.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

What happens when a biotech company tells investors one thing and delivers another? In this episode of Sue Wall Street, we unpack the securities class action against Savara Inc. $SVRA’s inhaled drug for rare lung disease was supposed to be a breakthrough—until the FDA refused to even review their application. If you're a biotech investor, compliance nerd, or just love a good Wall Street unraveling, this deep dive is for you.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

Was $LNTH hiding the truth? In this episode of Sue Wall Street, Cassie and Bill unpack the shocking securities class action lawsuit against Lantheus Holdings. Biotech investors, this one’s for you: we dig into Pylarify’s pricing fallout, executive silence, and a stock freefall that left shareholders stunned. Expect sharp analysis, legal breakdowns, and just enough outrage to fuel your next portfolio check. Whether you’re into earnings calls, SEC filings, or drama on the NASDAQ, tune in.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

Tesla’s $TSLA Robotaxi dreams hit a legal speed bump. In this episode of Sue Wall Street, we dive deep into the securities class action targeting Tesla and Elon Musk. Shareholders allege misleading claims about autonomous driving tech, safety, and AI, all while the stock took a sharp turn. Perfect for investors, financial sleuths, and courtroom junkies. Expect insider details, analysis, and sharp banter.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Novo Nordisk $NVO promised blockbuster weight loss from its new drug CagriSema—touting 25% results. But when final trial data landed at 22.7%, investors were stunned. In this episode of Bulls & Betrayal, Anna and Nate dig into the class action lawsuit accusing Novo of misleading shareholders about trial design and results. Perfect for biotech investors, legal watchers, and pharma skeptics, this episode exposes the risks behind drug hype.

Add our WhatsApp Channel.

Visit ZLK.com for more info.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.